Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Arsenic Trioxide Upregulates Cereblon mRNA Expression and Potentiates Sensitivity of SKM-1 and MDS-L Cells to Lenalidomide

Radka Bokorová, Ota Fuchs, PhD, Denisa Myslivcova, PhD, Jaroslav Cermak

Blood (2019) 134 (Supplement_1): 5397.

https://doi.org/10.1182/blood-2019-126443

Published: 2019

Journal Articles

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, MSc, Jaroslav Polak, MSc, Anna Jonasova, MD, Radana Neuwirtova, MD PhD, Marie Lauermannova, MD, Jaroslav Cermak, MD PhD, Marketa Stastna, MD PhD, Cyril Salek, Dana Mikulenkova, MD, Zuzana Zemanova, PhD, Jana Brezinova, Kyra Michalova, PhD, Denisa Myslivcova, PhD, Ota Fuchs, PhD

Blood (2018) 132 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2018-99-115803

Published: 2018

Journal Articles

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, Jaroslav Polak, MSc, Arnost Kostecka, Anna Jonasova, MD PhD, Radana Neuwirtova, MD PhD, Tomas Stopka, MD PhD Assoc Proff, Marie Lauermannova, Jaroslav Cermak, MD PhD, Dana Mikulenkova, Zuzana Zemanova, PhD, Jana Brezinova, PhD, Ota Fuchs, PhD

Blood (2017) 130 (Supplement 1): 5295.

https://doi.org/10.1182/blood.V130.Suppl_1.5295.5295

Published: 2017

Journal Articles

Why Patients with 5q- Syndrome Have Thrombocythemia?

Vit Campr, MD PhD, Jan Stritesky, MD PhD, Ota Fuchs, PhD, Anna Jonasova, MD PhD, Zuzana Zemanova, PhD, Radana Neuwirtova, MD PhD

Blood (2016) 128 (22): 5533.

https://doi.org/10.1182/blood.V128.22.5533.5533

Published: 2016

Journal Articles

PD-L1 Is Frequently Expressed in Acute Myeloid Leukemia Patients with Leukocytosis

Barbora Brodská, PhD, Ota Fuchs, PhD, Petra Otevřelová, Cyril Salek, MD PhD, Kateřina Kuželová, PhD

Blood (2016) 128 (22): 5229.

https://doi.org/10.1182/blood.V128.22.5229.5229

Published: 2016

Journal Articles

The Good Prognosis and Positive Response to the Therapy of Patients with Two Unrelated Clones Del(5q) and Trisomy 8 Does Not Differ to That of the 5q- Syndrome. This Is in Contrast to the Bad Prognosis of Patients with the Same Chromosomal Aberrations in One Clone

Radana Neuwirtova, MD PhD As. Prof., Zuzana Zemanova, Jana Brezinova, PhD, Pavel Dvorak, MD, Ota Fuchs, PhD, Martin Vostry, Anna T Jonasova, MD, Jaroslav Cermak, MD PhD As. Prof., Dana Sponerova, MD, Zuzana Maskova, MD, Libor Cervinek, MD PhD, Vera Vozobulova, MD, Eva Polonyova, MD, Kyra Michalova, PhD Prof.

Blood (2014) 124 (21): 5626.

https://doi.org/10.1182/blood.V124.21.5626.5626

Published: 2014

Journal Articles

The Significance Of Fli1 and p53 For The Effective Megakaryopoiesis In 5q- Syndrome and The Effect Of Lenalidomide Treatment

Radana Neuwirtova, MD, PhD, Jan Stritesky, MD, PhD, Ota Fuchs, PhD, Martin Vostry, Arnost Kostecka, Monika Belickova, PhD, Magdalena Siskova, MD, PhD, Kyra Michalova, prof., PhD, Jaroslav Cermak, Ass. Prof., PhD, Anna T Jonasova, MD

Blood (2013) 122 (21): 5208.

https://doi.org/10.1182/blood.V122.21.5208.5208

Published: 2013

Journal Articles

CBFβ/MYH11 Hypomethylation Signature In Patients With Acute Myeloid Leukaemia

Hana Hajkova, Markus H.-Y. Fritz, Jiri Schwarz, Jana Markova, Martin Vostry, Zdenek Krejcik, Cyril Salek, Ota Fuchs, PhD, Petr Cetkovsky, Jaroslav Cermak, Cedrik Haskovec, Vladimir Benes

Blood (2013) 122 (21): 3774.

https://doi.org/10.1182/blood.V122.21.3774.3774

Published: 2013

Journal Articles

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

Anna T Jonasova, MD, Jaroslav Polak, Martin Vostry, Arnost Kostecka, Radka Bokorova, Radana Neuwirtova, MD, PhD, Magda Siskova, MD, Miroslav Caniga, Dana Sponerova, Jaroslav Cermak, Dana Mikulenková, MD, Jana Brezinova, PhD, Kyra Michalova, PhD, Ota Fuchs, PhD

Blood (2013) 122 (21): 1529.

https://doi.org/10.1182/blood.V122.21.1529.1529

Published: 2013

Journal Articles

The Significance of Megakaryocytic Transcription Factor Fli1 and Erythroid Transcription Factor EKLF in the Ribosomopathies: 5q Minus Syndrome and Diamond-Blackfan Anemia. the Role of Fli1 in p53 Regulation and in 5q Minus Syndrome Megakaryopoiesis,

Radana Neuwirtova, MD, PhD, Ota Fuchs, PhD, Dagmar Pospisilova, MD, PhD, Radek Cmejla, PhD, Monika Holicka, Martin Vostry, Arnost Kostecka, Hana Hajkova, Anna Jonasova, MD, Jaroslav Cermak, MD, PhD, Kyra Michalova, PhD, Jana Brezinova, PhD

Blood (2011) 118 (21): 3825.

https://doi.org/10.1182/blood.V118.21.3825.3825

Published: 2011

Journal Articles

Fli-1 and EKLF Gene Expression in Patients with MDS 5q- Syndrome.

Radana Neuwirtova, MD, PhD, Ota Fuchs, V, Dana Provaznikova, Jr., Jaroslav Cermak, V, Magda Siskova, III, Anna Jonasova, V, Kyra Michalova, IV

Blood (2009) 114 (22): 2788.

https://doi.org/10.1182/blood.V114.22.2788.2788

Published: 2009

Journal Articles

A Lack of Correlation between EVI1 Expression, MDS Subtype and Karyotype Abnormalities Suggests Multiple Pathways Involved in EVI1 Impact on Hematopoietic Cells in MDS Patients.

Jaroslav Cermak, MD, PhD, Ota Fuchs Ing, PhD, Dana Provaznikova, PhD, Kyra Michalova, PhD, Dana Mikulenkova, MD, Jana Brezinova, RNDr PhD, Pavel Klener, MD, PhD

Blood (2007) 110 (11): 2441.

https://doi.org/10.1182/blood.V110.11.2441.2441

Published: 2007

Journal Articles

Differential Induction of Apoptosis in Human Leukemia Cells (ML-1, ML-2, CTV-1 and KASUMI-1) Exposed to the Proteasome Inhibitor Bortezomib and the Effect of Transforming Growth Factor-beta Signaling Pathway.

Ota Fuchs, PhD, Dana Provaznikova, MS, Gabriela Peslova, MS, Marcela Kocova, MS, Iuri Marinov, MD, Ivan Spicka, MD

Blood (2006) 108 (11): 4359.

https://doi.org/10.1182/blood.V108.11.4359.4359

Published: 2006

Journal Articles

Increased Expression of Genes for Protooncoproteins SnoN and SnoA in Human Myeloblastic Leukemia ML2 Cells and Resistance of ML2 Cells to Transforming Growth Factor-beta-Induced Growth Arrest.

Ota Fuchs, Gabriela Peslova, Dana Provaznikova, Iuri Marinov

Blood (2005) 106 (11): 4347.

https://doi.org/10.1182/blood.V106.11.4347.4347

Published: 2005

NARROW

Arsenic Trioxide Upregulates Cereblon mRNA Expression and Potentiates Sensitivity of SKM-1 and MDS-L Cells to Lenalidomide

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Why Patients with 5q- Syndrome Have Thrombocythemia?

PD-L1 Is Frequently Expressed in Acute Myeloid Leukemia Patients with Leukocytosis

The Good Prognosis and Positive Response to the Therapy of Patients with Two Unrelated Clones Del(5q) and Trisomy 8 Does Not Differ to That of the 5q- Syndrome. This Is in Contrast to the Bad Prognosis of Patients with the Same Chromosomal Aberrations in One Clone

The Significance Of Fli1 and p53 For The Effective Megakaryopoiesis In 5q- Syndrome and The Effect Of Lenalidomide Treatment

CBFβ/MYH11 Hypomethylation Signature In Patients With Acute Myeloid Leukaemia

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

The Significance of Megakaryocytic Transcription Factor Fli1 and Erythroid Transcription Factor EKLF in the Ribosomopathies: 5q Minus Syndrome and Diamond-Blackfan Anemia. the Role of Fli1 in p53 Regulation and in 5q Minus Syndrome Megakaryopoiesis,

Fli-1 and EKLF Gene Expression in Patients with MDS 5q- Syndrome.

A Lack of Correlation between EVI1 Expression, MDS Subtype and Karyotype Abnormalities Suggests Multiple Pathways Involved in EVI1 Impact on Hematopoietic Cells in MDS Patients.

Differential Induction of Apoptosis in Human Leukemia Cells (ML-1, ML-2, CTV-1 and KASUMI-1) Exposed to the Proteasome Inhibitor Bortezomib and the Effect of Transforming Growth Factor-beta Signaling Pathway.

Increased Expression of Genes for Protooncoproteins SnoN and SnoA in Human Myeloblastic Leukemia ML2 Cells and Resistance of ML2 Cells to Transforming Growth Factor-beta-Induced Growth Arrest.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only